Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20074229 | 0.83 | KMT2A (0.44) | RAB9ANPC1KMT2ALMNAMAPT | |
| SCHEMBL24418198 | 0.82 | P2RY12 (0.40) | OGACYP2C9CYP2C19RAB9ANPC1 | |
| SCHEMBL31352440 | 0.82 | ACHE (0.59) | OGACYP2C9CYP2C19RAB9ANPC1 | |
| Fluoride SCHEMBL14796503 | 0.80 | ACHE (0.43) | ACHEKMT2ALMNACYP4F2CYP4A11 | |
| SCHEMBL5139638 | 0.80 | ACHE (0.43) | ACHEKMT2ALMNACYP4F2CYP4A11 | |
| SCHEMBL29218328 | 0.79 | ACHE (0.43) | CYP2C9HPGDACHELMNACYP4F2 | |
| SCHEMBL6519027 | 0.79 | ACHE (0.46) | ACHELMNAMAPTCYP4F2CYP4A11 | |
| SCHEMBL22979376 | 0.79 | ACHE (0.56) | OGACYP2C9CYP2C19RAB9ANPC1 | |
| SCHEMBL23600914 | 0.79 | MGLL (0.40) | LMNACYP4F2CYP4A11KDM5BRXRA | |
| SCHEMBL17437956 | 0.79 | OGA (0.53) | OGACYP2C9CYP2C19RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-114555556-B | Process for preparing CFTR modulators | 弗特克斯药品有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| CN-114555556-A | Methods of making CFTR modulators | 弗特克斯药品有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2013144191-A1 | SUBSTITUTED 2-AMINO-3-CYANOPYRIDINES AS INHIBITORS OF SODIUM-CALCIUM EXCHANGE AND USE THEREOF FOR CARDIOVASCULAR DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | OGA 3937/4885CYP2C9 40/4885CYP2C19 52/4885 |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | OGA 3841/4885CYP2C9 3624/4885CYP2C19 3070/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | OGA 3937/4885CYP2C9 40/4885CYP2C19 52/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | OGA 3937/4885CYP2C9 40/4885CYP2C19 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.